October 13, 2009 (Durham, North Carolina) — Carriers of the reduced-function single nucleotide polymorphism (SNP) of the SLCO1B1 gene are at an increased risk of developing mild statin-induced side ...
July 24, 2008 — A new genomewide-association study has identified a genetic risk factor for myopathy in patients who are being treated with statins to lower LDL-cholesterol levels [1]. Investigators ...
Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified ...
Over 250,000 Genotypes Performed to Help Identify Individual Risk of Statin Induced Myopathy; Data Confirm Research Findings of Risk Prevalence for Statin Side Effects FRAMINGHAM, Mass., Boston Heart ...
Researchers at the VA Boston Healthcare System, Brigham and Women’s Hospital, and Harvard Medical School conducted a randomized controlled trial of pharmacogenetic testing related to statins, such as ...
December 6, 2011 – The use of genetic tests to predict a patient's response to drugs is increasingly important in the development of personalized medicine. But genetic tests often only look for the ...
Boston Heart Diagnostics announced the launch of the Statin Induced Myopathy (SLCO1B1) Genotype test, which identifies patients who are at higher risk for developing severe myopathy (muscle aches and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results